Astrazeneca PLC (AZN): Price and Financial Metrics
Astrazeneca PLC (AZN)
Today's Latest Price: $54.92 USD
Updated Sep 30 1:59pm
Add AZN to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 239 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
AZN Stock Summary
- With a market capitalization of $145,658,240,000, Astrazeneca Plc has a greater market value than 98.92% of US stocks.
- With a one year PEG ratio of 671.43, Astrazeneca Plc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 95.15% of US stocks.
- In terms of volatility of its share price, AZN is more volatile than just 5.67% of stocks we're observing.
- Stocks that are quantitatively similar to AZN, based on their financial statements, market capitalization, and price volatility, are AMGN, NVO, LLY, SNY, and MDT.
- Visit AZN's SEC page to see the company's official filings. To visit the company's web site, go to www.astrazeneca.com.
AZN Stock Price Chart Technical Analysis Charts
AZN Price/Volume Stats
| Current price | $54.92 | 52-week high | $64.94 |
| Prev. close | $55.11 | 52-week low | $36.15 |
| Day low | $54.75 | Volume | 2,096,976 |
| Day high | $55.45 | Avg. volume | 5,220,584 |
| 50-day MA | $55.64 | Dividend yield | 1.6% |
| 200-day MA | $51.39 | Market Cap | 144.13B |
Astrazeneca PLC (AZN) Company Bio
AstraZeneca plc engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. The company was founded in 1992 and is based in London, the United Kingdom.
AZN Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $54.92 | $14.1 | -75% |
Below please find a table outlining a discounted cash flow forecast for AZN, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Astrazeneca Plc ranked in the 18th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Astrazeneca Plc ended up being:
- The company's compound free cash flow growth rate over the past 5.48 years comes in at -0.12%; that's greater than only 13.19% of US stocks we're applying DCF forecasting to.
- The company has produced more trailing twelve month cash flow than 89.97% of its sector Healthcare.
- Astrazeneca Plc's weighted average cost of capital (WACC) is 8%; for context, that number is higher than just 23.73% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -75% |
| 1% | -75% |
| 2% | -75% |
| 3% | -74% |
| 4% | -74% |
| 5% | -74% |
DHR, TFX, ABC, ICUI, and EHC can be thought of as valuation peers to AZN, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...